Cutler Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Cutler Group’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-193	Closed	-$6K	–	5664
2020 Q3	$6K	Buy	+193	New	+$60K	﹤0.01%	3420

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

AWP

Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Cutler Group's EIGR Position: Q1 2024 in Review

Cutler Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 33 shares.

Cutler Group first reported a position in EIGR in Q4 2015 and held it in 13 quarters. The position peaked at $26K in Q4 2015. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

Cutler Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 33 Eiger BioPharmaceuticals, Inc. shares in Q1 2024.
Cutler Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2015 and held it in 13 quarters.
Cutler Group's Eiger BioPharmaceuticals, Inc. position peaked at $26K in Q4 2015.
24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.